MALVERN, Pa., Jan. 10, 2022 (GLOBE NEWSWIRE) — Neuronetics, Inc. (NASDAQ: STIM), a industrial stage medical know-how firm targeted on designing, creating, and advertising and marketing merchandise that enhance the standard of life for sufferers who are suffering from neurohealth issues, at present introduced sure preliminary unaudited fourth quarter and full yr 2021 income outcomes.
Fourth Quarter 2021
Preliminary unaudited complete income for the fourth quarter of 2021 is anticipated to be within the vary of roughly $14.5 to $15.0 million as in comparison with beforehand acknowledged steering of $13.0 to $14.0 million.
Full 12 months 2021
Preliminary unaudited complete income for the complete yr 2021 is anticipated to be within the vary of roughly $54.8 to $55.3 million as in comparison with beforehand acknowledged steering of $53.3 to $54.3 million.
“Regardless of the headwinds related to COVID-19 that endured in 2021, our group delivered sturdy efficiency within the fourth quarter, primarily on account of elevated therapy session volumes throughout our buyer base and strong demand for brand new techniques,” stated Keith J. Sullivan, President and Chief Govt Officer of Neuronetics. “All year long, we made vital progress on a number of of our strategic initiatives setting ourselves as much as drive future progress, together with getting into into new, unique, industrial agreements with a number of nationwide accounts. Whereas the macro atmosphere continues to be fluid, we’re very enthusiastic about our prospects for 2022. We plan to capitalize on our sturdy momentum going into the yr and are assured in our group’s means to drive the widespread adoption of NeuroStar Superior Remedy for Psychological Well being.”
Neuronetics, Inc. believes that psychological well being is as vital as bodily well being. As a worldwide chief in neuroscience and the biggest TMS firm within the business, Neuronetics is redefining affected person and doctor expectations by designing and creating merchandise that enhance the standard of life for individuals affected by psychiatric issues. An FDA-cleared, non-drug, noninvasive therapy for individuals with despair, Neuronetics’ NeuroStar® Superior Remedy system is at present’s main transcranial magnetic stimulation (TMS) therapy for main depressive dysfunction with over 4 million remedies delivered. NeuroStar is extensively researched and backed by the biggest scientific information set of any TMS system for despair, together with the world’s largest despair Outcomes Registry. Neuronetics is dedicated to reworking lives by providing an distinctive therapy possibility that produces extraordinary outcomes. For security data and indications to be used, go to NeuroStar.com.
“Protected harbor” assertion beneath the Non-public Securities Litigation Reform Act of 1995:
Statements within the press launch relating to Neuronetics, Inc. (the “Firm”) that aren’t historic information represent “forward-looking statements” throughout the which means of the Non-public Securities Litigation Reform Act of 1995. These forward-looking statements could also be recognized by phrases similar to “outlook,” “potential,” “imagine,” “count on,” “plan,” “anticipate,” “predict,” “might,” “will,” “might,” “would” and “ought to” in addition to the detrimental of those phrases and comparable expressions. These statements embody these referring to: the Firm’s enterprise outlook and present expectations for the fourth quarter 2021 and financial yr 2021, together with with respect to income and any underlying assumptions. These statements are topic to vital dangers and uncertainties and precise outcomes might differ materially from these projected. The Firm cautions traders to not place undue reliance on the forward-looking statements contained on this launch. These dangers and uncertainties embody, with out limitation, dangers and uncertainties associated to: the influence of COVID-19 on the Firm’s operational and price range plans in addition to common political and financial circumstances, together with on account of efforts by governmental authorities to mitigate COVID-19, similar to journey bans, shelter in place orders and third-party enterprise closures and the associated influence on useful resource allocations, manufacturing and provide chains and affected person entry to industrial merchandise; the Firm’s means to execute its enterprise continuity; the Firm’s means to attain or maintain worthwhile operations as a result of its historical past of losses; the Firm’s reliance on the sale and utilization of its NeuroStar Superior Remedy for Psychological Well being System to generate revenues; the size and efficacy of the Firm’s salesforce; availability of protection and reimbursement from third-party payors for remedies utilizing the Firm’s merchandise; doctor and affected person demand for remedies utilizing the Firm’s merchandise; developments in respect of competing applied sciences and therapies for the indications that the Firm’s merchandise deal with; product defects; the Firm’s means to acquire and preserve mental property safety for its know-how; developments in scientific trials or regulatory evaluate of NeuroStar Superior Remedy for Psychological Well being System for extra indications; and developments in regulation in america and different relevant jurisdictions. For a dialogue of those and different associated dangers, please confer with the Firm’s current SEC filings which can be found on the SEC’s web site at www.sec.gov. These forward-looking statements are based mostly on the Firm’s expectations and assumptions as of the date of this press launch. Besides as required by regulation, the Firm undertakes no responsibility or obligation to replace any forward-looking statements contained on this press launch on account of new data, future occasions, or modifications within the Firm’s expectations.
Mike Vallie or Mark Klausner